Klin Farmakol Farm. 2025;39(3):150-154 | DOI: 10.36290/far.2025.057
Beta-blockers in the treatment of arterial hypertension
- I. interní kardioangiologická klinika, FN u sv. Anny v Brně, LF MU Brno
Beta-blockers represent a traditional class of antihypertensive drugs, whose role in the treatment of arterial hypertension has evolved significantly over recent decades. While they are no longer recommended as first-line therapy for uncomplicated hypertension, they remain a key treatment option in certain clinical scenarios - particularly in patients with concomitant ischemic heart disease, a history of myocardial infarction, heart failure, tachyarrhythmias, or increased sympathetic activity in younger individuals. This review aims to summarize the mechanism of action of beta-blockers, evaluate available clinical evidence of their efficacy, compare them to other antihypertensives, and present their current role in accordance with the latest ESH 2023, ESC 2024, and Czech Hypertension Society 2022 guidelines.
Keywords: beta-blockers, arterial hypertension, antihypertensive drugs, ischemic heart disease, guidelines.
Accepted: October 23, 2025; Published: October 30, 2025 Show citation
References
- Mancia G, Kreutz R, Brunström M, et al. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). J Hypertens. 2023;41(12):1874-2071.
Go to original source... - McEvoy JW, McCarthy CP, Bruno RM, et al. 2024 ESC Guidelines for the management of elevated blood pressure and hypertension: Developed by the task force on the management of elevated blood pressure and hypertension of the European Society of Cardiology (ESC) and endorsed by the European Society of Endocrinology (ESE) and the European Stroke Organisation (ESO). Eur Heart J. 2024;ehae178.
- Widimský J. Nová doporučení diagnostických a léčebných postupů u arteriální hypertenze České společnosti pro hypertenzi 2022: stručný komentář. Hypertenze Kardiovaskulární Prevence. 2022;12(2):75-75.
- Dahlöf B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet Lond Engl. 2005;366(9489):895-906. Go to original source...
- Dahlöf B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet Lond Engl. 2002;359(9311):995-1003. Go to original source...
- Wiysonge CS, Bradley H, Mayosi BM, et al. Beta-blockers for hypertension. Cochrane Database Syst Rev. 2007;(1):CD002003. Go to original source...
- Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ. 2009;338:b1665. Go to original source...
- Fonseca VA. Effects of beta-blockers on glucose and lipid metabolism. Curr Med Res Opin. 2010;26(3):615-629. Go to original source...
- Manisty CH, Zambanini A, Parker KH, et al. Differences in the magnitude of wave reflection account for differential effects of amlodipine- versus atenolol-based regimens on central blood pressure: an Anglo-Scandinavian Cardiac Outcome Trial substudy. Hypertens Dallas Tex 1979. 2009;54(4):724-730. Go to original source...
- Kveiborg B, Christiansen B, Major-Petersen A, et al. Metabolic effects of beta-adrenoceptor antagonists with special emphasis on carvedilol. Am J Cardiovasc Drugs Drugs Devices Interv. 2006;6(4):209-217. Go to original source...
- Prichard BN, Gillam PM. Use of propranolol (inderal) in treatment of hypertension. Br Med J. 1964;2(5411):725-727. Go to original source...
- Karmali KN, Lloyd-Jones DM, van der Leeuw J, et al. Blood pressure-lowering treatment strategies based on cardiovascular risk versus blood pressure: A meta-analysis of individual participant data. PLoS Med. 2018;15(3):e1002538. Go to original source...
- Chan You S, Krumholz HM, Suchard MA, et al. Comprehensive Comparative Effectiveness and Safety of First-Line β-Blocker Monotherapy in Hypertensive Patients: A Large-Scale Multicenter Observational Study. Hypertens Dallas Tex 1979. 2021;77(5):1528-1538. Go to original source...